• Silexion Therapeutics reported new preclinical data for SIL204 showing immune-sensitizing effects in KRAS-mutant pancreatic cancer and NSCLC cell lines.
• SIL204 increased FAS (CD95) expression at 72 hours, including up to about 2-fold in KRAS G12D pancreatic cells (P<0.0001).
• SIL204 reduced HLA-G expression in KRAS G12C NSCLC cells, including at 24 hours (P<0.001) and 72 hours (P<0.01) at 200 nM.
• Results build on May 2026 findings of MHC-I upregulation, supporting a combination rationale with anti-PD-(L)1 checkpoint inhibitors.
• The company is advancing SIL204 into Phase 2/3 evaluation, citing initiation of its first clinical trial site in late July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003796), on August 04, 2026, and is solely responsible for the information contained therein.